Development and validation of a UHPLC-ESI-MS/MS method for the simultaneous quantification of mammal lysophosphatidylcholines and lysophosphatidylethanolamines in serum.
Recent investigations based on non-targeted metabolomics have proposed lysophospholipids (Lyso-PLs) as biomarkers of different diseases. In particular, lysophosphatidylcholines (Lyso-PCs) and lysophosphatidylethanolamines (Lyso-PEs) have been associated with serious lipid pathologies. Methods to determine the different molecular species in a biological sample and to quantify even less abundant species are required for the evaluation of the Lyso-PL pattern as a novel comprehensive biomarker of dyslipidemia. This study describes the development and validation of an ultra-high-performance liquid chromatography coupled to tandem mass spectrometry assay for the determination of a large number of Lyso-PCs and Lyso-PEs in biological samples. The method was validated in rat serum using two simple methanol-based extractions with low sample volumes (5-50μL) that covered the wide concentration range of these metabolites. In total, thirty-one Lyso-PLs were separated and quantified with low method limits of detection and quantification, reaching values of 0.2 and 0.8nM, respectively. The method was subsequently applied in the identification of Lyso-PL-related changes produced by the chronic intake of a cafeteria diet. The results showed alterations in the majority of Lyso-PCs and Lyso-PEs in rat serum. Furthermore, multivariate analysis indicated that the comprehensive evaluation of serum Lyso-PLs could be an excellent indicator of the nutritional phenotype associated with an increased risk of lipid disorders.